Arteanoflavone Has an Inhibitory Effect on Platelet Aggregation Through Regulation of Phosphorylated Proteins in U46619-induced Human Platelets

Cardiovascular disease (CVD) is a major cause of death worldwide and is on the rise, and one of the causes is excessive formation of blood clots when blood vessel damage occurs. Recently, interest in antithrombotic substances through platelet inhibition is growing, and efforts are made to decrease side effects by adapting natural bioactive compounds. Arteanoflavone, a compound extracted from Artemisia iwayomogi, has increasingly been demonstrated to have anti-inflammatory, antioxidant, and anti-allergic properties in recent studies. However, little research has been done on the effects and mechanisms of arteanoflavone on platelet activation and aggregation, so this study aimed to determine the effects of arteanoflavone on platelet activation and aggregation. Arteanoflavone strongly inhibited the phosphorylation of phosphorylated proteins such as PI3K/Akt and MAPK pathway proteins and cPLA₂ during platelet signaling, which led to a decrease in granule secretion in platelets including ATP and serotonin. As a result, it was found that arteanoflavone strongly inhibits platelet aggregation induced by the aggregation inducer U46619 with an ICSUB50/SUB of 76.64 μM. Therefore, through this study, we suggest that arteanoflavone may be an effective agent to inhibit the activation and aggregation of human platelet that occurs through vascular damage.